- Home
- CRAN vs AVIR Comparison
CRAN vs AVIR Comparison
Compare CRAN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRAN | AVIR |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.6M | 429.1M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRAN | AVIR |
|---|---|---|
| Price | $10.14 | $5.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 178.3K | ★ 207.3K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $2.78 |
| 52 Week High | $10.21 | $6.45 |
Technical Indicators
Market Signals| Indicator | CRAN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 67.43 |
| Support Level | $10.13 | $4.14 |
| Resistance Level | N/A | $6.37 |
| Average True Range (ATR) | 0.01 | 0.20 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 66.67 | 83.08 |
Price Performance
Historical ComparisonAbout CRAN Crane Harbor Acquisition Corp. II Class A Ordinary Shares
Crane Harbor Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.